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Abstract
Background: In sub-Saharan Africa, Plasmodium falciparum and hepatitis A (HAV) infections are common, especially in
children. Co-infections with these two pathogens may therefore occur, but it is unknown if temporal clustering exists.
Materials and Methods: We studied the pattern of co-infection of P. falciparum malaria and acute HAV in Kenyan children
under the age of 5 years in a cohort of children presenting with uncomplicated P. falciparum malaria. HAV status was
determined during a 3-month follow-up period.
Discussion: Among 222 cases of uncomplicated malaria, 10 patients were anti-HAV IgM positive. The incidence of HAV
infections during P. falciparum malaria was 1.7 (95% CI 0.81–3.1) infections/person-year while the cumulative incidence of
HAV over the 3-month follow-up period was 0.27 (95% CI 0.14–0.50) infections/person-year. Children with or without HAV
co-infections had similar mean P. falciparum asexual parasite densities at presentation (31,000/mL vs. 34,000/mL,
respectively), largely exceeding the pyrogenic threshold of 2,500 parasites/mL in this population and minimizing risk of over-
diagnosis of malaria as an explanation.
Conclusion: The observed temporal association between acute HAV and P. falciparum malaria suggests that co-infections of
these two hepatotrophic human pathogens may result from changes in host susceptibility. Testing this hypothesis will
require larger prospective studies.
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Introduction
In Africa, both Plasmodium falciparum malaria and hepatitis A virus
(HAV) infections are common infections, especially in children
[1,2], although concurrent infections of these two highly prevalent
human pathogens are likely to occur, knowledge about their
prevalence and potential significance is poor. Since both pathogens
target the hepatocyte as host cell for intracellular replication
(mosquito-transmitted malaria parasites replicate silently in suitable
hepatocytes before red blood cell invasion) direct or immunolog-
ically mediated interactions in concurrent infections could poten-
tially escalate or inhibit progression of both infections.
Epidemiologically relevant interactions, though with contradic-
tory findings, have previously been shown for P. falciparum malaria
and hepatitis B (HBV). In a case-control study in The Gambia, the
prevalence of HBV was significantly increased amongst children
with severe P. falciparum malaria compared to matched controls [3].
Barcus et al found a prevalence of HBV infection of 24% in adult
Vietnamese patients admitted with severe P. falciparum malaria,
whichwashigherthantheestimatedprevalenceofHBVinthatarea
(10%) [4]. In contrast, a study in Papua New Guinea showed that
female adults with the highest spleen rates of Plasmodium had the
lowest prevalence of HBV infection, but there was no correlation
with parasitemia [5]. Pasquetto et al showed a reduction of HBV
replication rate, and ultimately, clearance of virions, in mice co-
infected with P. yoelii [6]. It is also known that co-infections of other
viruses such as Ebstein-Barr Virus [7,8], and HIV [9] with P.
falciparum affect the natural course of P. falciparum infections.
In this study we aimed to determine the temporal pattern of co-
infection of P. falciparum malaria and acute HAV in a cohort of
Kenyan children under the age of 5 years presenting with
uncomplicated P. falciparum malaria. We focused on HAV since an
initial viral screen (hepatitis A, B, C and D virus) of cases with
elevated plasma concentrations of alanine aminotransferase (ALT;
an established biomarker for the extent of liver cell damage)
patients were positive for HAV, but not for any other hepatitis
viruses.
Results
A total of 222 children were included in this study. Forty
patients (18.0%) had ALT plasma concentrations above the upper
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measurements at enrolment or during follow-up, and fifteen
patients (6.7%) had ALT levels exceeding 100 U/L. All ten cases
of HAV occurred in patient with ALT levels above 36 U/L (range
41–1295 U/L): eight patients had ALT levels $100 U/L, and two
children had maximal ALT levels between 36–100 U/L (41 and
56 U/L). Demographic and laboratory data of HAV positive and
negative children are shown in Table 1.
We also tested the presence of IgM-HAV antibodies in 15
patients with normal ALT levels (#36 U/L). These children were
matched on treatment, study date, gender and age with the 15
patients having ALT levels $100 U/L. None of these patients
showed a positive reaction for IgM-HAV. In addition, we tested an
alternative hypothesis that falciparum malaria infections can lead to
increased production of unspecific HAV-IgM [10] potentially
causing false positive test results. We therefore measured 14
samples with the highest P. falciparum parasite density at baseline
(of whom six children also belonged to the matched controls). The
geometrical mean parasitemia in this subgroup was 196,000
parasites/mL (95% CI=177,000–217,000; range=164,000–
350,000), and the median ALT level was 28 U/L (range 16–
194 U/L). One patient with a parasitemia of 202,000/mL and a
maximal ALT level of 41 U/L (case #10 in Table 2) showed a
positive reaction. This indicated that elevated ALT plasma
concentrations above 100 U/L had acceptable sensitivity (8/15,
53%) and high specificity (61/63, 97%), and levels above 36 U/L
had low sensitivity (10/55, 18%) but excellent specificity (23/23,
100%) for detecting HAV infections in our cohort. As all available
samples with ALT levels above the cut-off value of 36 U/L were
measured, it is unlikely that we missed any additional HAV-
positive cases.
Importantly, all but one case coincided with malaria (8 during
first week and 1 on malaria reinfection; cases #1–7 and cases #9–
10 in Table 2). The other case (case #8) had elevated ALT levels
at day 84, indicating that a possible re-infection, if having occurred
in this patient, could not have be detected due to end of follow-up.
Thus, the number of HAV positive patients in this cohort of
children in the 3-month follow-up period was 10 cases per 37.3
person-years (222 children with an average follow-up time of 2.0
months) resulting in a cumulative incidence of 0.27 (95% CI 0.14–
0.50) infections per person-year, while during malaria there were 9
HAV-positive cases per 5.4 person-years, resulting in an incidence
of 1.7 (95% CI 0.81–3.1) HAV infections per person-year. In the
latter case, we calculated the incidence rate based on a 1-week
time frame, that is, during and shortly after the malaria episode,
and took into account all malaria episodes during baseline and all
73 recurrences that occurred during follow-up of the cohort of 222
children. The choice of a 1-week time frame thus resulted in an
artificial saturation of the incidence rate (.1 infection per person-
year) in a disease with 100% immunity. However, using this unit
we obtained a realistic estimate for the incidence rate of HAV
infections in children during the convalescence phase (0.27 per
person-year), which is consistent with estimates that nearly all
children in this part of Africa will have experienced an infection
before the age of 5 years [2]. The proportion of children with
elevated ALT levels differed significantly between baseline (60/
Table 1. Comparison of HAV positive and negative patients presenting with uncomplicated P. falciparum malaria.
HAV positive (n=10) HAV negative (n=68) p-value
Age (months) (mean 6 SD) 26.1611.8 28.9614.1 0.549
#
Weight (kg) (mean 6 SD) 10.562.13 10.862.41 0.734
#
Sex (male/female) (number) 6/4 37/31 0.491
1
Treatment (DHA-piperaquine/artemether-
lumefantrine) (number)
8/2 48/20 0.534
1
Baseline laboratory data
Parasitemia (/mL) (geomean695%CI) 37,000 (17,000–79,000)
‘ 48,000 (33,000–64,000)
{ 0.551*
Hemoglobin (g%) (mean 6 SD) 8.161.8 9.261.4 0.031
#
WBC count (/mL) (median, IQR) 8.7 (7.7–14.4) 9.0 (6.7–11.8) 0.774*
Creatinine (mmol/L) (mean 6 SD) 3866.5 4369.6 0.144
#
Total bilirubin (mmol/L) (median, IQR) 14.8 (12.3–23.6) 13.8 (8.8–24.6) 0.679*
ALT (U/L) at
D0 (median (IQR)) 92 (36–173) 29 (22–45) 0.016*
D3 (median (IQR)) 64 (40–235) 28 (22–47) 0.028*
D7 (median (IQR)) 81 (53–416) 21 (17–52) 0.012*
D28 (median (IQR)) 27 (23–64) 23 (18–31) 0.385*
D42 (median (IQR)) 21 (19–27) 24 (21–31) 0.270*
D84 (median (IQR)) 26 (24–171) 27 (20–36) 0.599*
Recurrent P .falciparum infections (number) 5 19 0.374
1
Geometric mean parasitemia at baseline were
‘31,000 (15,000–63,000) and
{34,000 (24,000–47,000) when patients with high parasitemia are excluded.
#T-test,
*Mann-Whitney test,
1chi square test.
doi:10.1371/journal.pone.0021013.t001
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95%CI 7.6–26.3%; P=0.001). A possible explanation could be
the aggregation of measurements from baseline to day 7, because
when only data from baseline were used, the difference ceased to
be significant (39/222; difference, 7.5%, 95%CI 21.4%–16.3%;
P=0.119), possibly indicating that other factors such as treatment
could have caused the additional increase in ALT levels.
Only one child with acute HAV infection showed clinical
symptoms of the infection, i.e., jaundice; this patient had the
highest ALT plasma concentration (case #6 in Table 2). None of
the other children had clinical signs or symptoms suggestive of
viral hepatitis infection, apart from fever, which is the main clinical
symptom of malaria. Fever clearance times were similar between
HAV positive and negative patients (1.0 versus 1.1 days,
respectively).
Fifty percent (5/10) of patients with HAV infection had a P.
falciparum malaria recurrence, compared to 35 percent (19/54) of
HAV uninfected patients (p=0.37). Of the five patients with a
malaria recurrence in the HAV positive group, four were found to
be HAV infected at baseline; the other patient had an HAV
infection at day 42 and experienced a recurrent P. falciparum
infection 1 week later. Four patients had a re-infection; the other
sample could not be analyzed. Of the 19 HAV negative patients
with a malaria recurrence, 17 had a re-infection, 1 had both
recrudescent primary and secondary re-infections, and 1 sample
could not be analyzed.
Discussion
The present study describes a temporal association between P.
falciparum malaria and acute HAV in a cohort of pediatric patients.
We found that nine out of ten cases of acute HAV infections
occurred simultaneously with P. falciparum malaria infections.
What are the alternative explanations that could have lead to a
potential overestimation of the temporal association of active HAV
infections with uncomplicated P. falciparum malaria? Firstly,
overestimation of the association might have occurred if patients
with HAV infections presented primarily for seeking relief for
symptomsofHAVinfection,and not ofmalaria.The baseline blood
stage density in our study group was high (.37,000 asexual
parasites/mL), far exceeding the pyrogenic threshold of 2,500
parasites/mL in this population and thus, minimizing over-diagnosis
of malaria as an alternative explanation [11,12]. Moreover, most
HAV infections inchildren below the age of 5 years are known to be
asymptomatic [13] and indeed, patients with co-infections did not
differ in times to symptom clearance compared to patients with P.
falciparum mono-infections. Secondly, P. falciparum malaria and/or
hepatotoxic side effects of antimalarial drugs can also lead to
elevated plasma concentrations of liver enzymes, indicating
hepatocellular damage [14]. This could have led to an overestima-
tion of the temporal association, as samples were selected based on
ALT levels. However, patients with high and low baseline parasite
densities had similar ALT levels and HAV infections clustered in
patients with elevated ALT concentrations, but not in matched
controls (matched on treatment, study date, gender and age).
Thirdly, false positive results could have been caused by an
induction of unspecific IgM antibody production leading to false
positive anti-HAV IgM test results. We addressed this question by
measuring IgM antibodies in 14 patients with the highest blood
stage parasite density at baseline. This could possibly have led to
misclassification bias. However, even if this is true and this patient is
regarded to be HAV negative, we still find a significant incidence
rateratio. The risk of more false positive cases is limited, as the three
highest parasitemias amongst the HAV positive children are
216,000/mL (the child who tested positive), 130,000/mL, and
125,000/mL. The latter two values are much lower than the
parasitemia of the patient who tested positive and also lower than
the parasitemia of the patient with the highest parasitemia in the
HAV negative group (170,000/mL). In addition, the ALT levels of
these patients were among the highest of the group (330 and
1300 UI/L) making an alternative diagnosis than acute HAV very
unlikely. Fourthly, an overestimation of the association with malaria
may have occurred, if anti-HAV IgM remains positive (long) after
viral HAV particles have been cleared from the liver. However, the
anti-HAV IgM response becomes undetectable usually within 6
months [15], but HAV RNA can be detected for more than 400–
600 days after ALT peak [16,17]. So even if anti-HAV IgM stays
positive for a longtime after acute infection, viralHAV particles will
be residing in hepatocytes during that time period; therefore
Table 2. Summary of key laboratory parameters of patients who presented with uncomplicated P. falciparum malaria and
subsequently found to have anti-HAV IgM indicating acute HAV infection.
Case #
Date of
inclusion in
study
1
HAV
detected (day) Age (months) ALT (U/L)
Baseline
asexual
parasite
density (/mL)
Asexual P.
falciparum
parasite
recurrence (day)
Day 0 Day 3 Day 7 Day 28 Day 42 Day 84
1 29/05/06 0 11 114 48 - 13 25 26 20,000 -
2 23/01/06 42 17 13 15 82 121 29 - 62,000 49
3 04/05/06 0 18 134 71 39 - 21 25 13,000 -
4 05/05/06 0 22 330 235 123 - 18 - 130,000 42
5 25/05/06 0 22 290 187 58 26 19 24 17,000 28
6 07/04/06 0 26 69 236 1295 45 21 - 126,000 -
7 18/05/06 0 28 118 327 80 27 - 42 19,000 35
8 06/12/05 84 38 25 44 - - 21 559 20,000 -
9 11/10/05 0 28 40 56 - - 17 - 14,000 -
10 05/05/06 0 52 41 29 - 27 29 23 202,000 56
1One-third of patients were enrolled in May 2006.
doi:10.1371/journal.pone.0021013.t002
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and malaria. We could also rule out the possibility of an outbreak of
HAV infection since patients were enrolled continuously from 2005
to 2006 and HAV cases did not cluster during a particular period of
the year.
We found that HAV infections were a common cause for
elevated plasma concentrations of an established biomarker of
liver cell damage (ALT) in these patients. Children from the Kilifi
district with P. falciparum malaria and elevated ALT concentrations
(.100 U/L) had a 53% (8/15) chance of being co-infected with
HAV, indicating that almost 50% of elevations could not be
explained by HAV infections. This percentage is high and
warrants consideration whenever determining the safety profile
of antimalarial drugs. This study did not reveal any adverse
clinical consequences of concurrent infections, except for a
significant lower hemoglobin level. We have no ready explanation
for this difference. Unlike Plasmodium infections HAV is not known
to affect hemoglobin levels. One could speculate that Plasmodium
infections in co-infected children were protracted and thus caused
a slight additional drop in hemoglobin concentrations. Malaria
patients co-infected with HAV were as likely as patients without
HAV co-infections to clear clinical symptoms and parasites. By
extension, this also indicates that most HAV infections were
asymptomatic as expected [13]. There was only one HAV case
with highly elevated ALT and clinical symptoms suggestive of
acute hepatitis, which developed during the treatment of malaria.
The biological mechanism, if any, behind the observed temporal
association remains elusive. For instance, P. falciparum liver stage
and/orblood stage infectionscould,mediatedby unknown immune
mechanisms, promote HAV replication and thus, increase the
chance to detect active HAV infections. Alternatively, coincidental
HAV infection could facilitate parasite survival at the liver stage
leading to increased numbers of infective merozoites and higher
likelihood of subsequent pathogenic blood stage infection, in a
similar wayto the suggested mechanismforthe observed association
between malaria and HBV. In the study by Thursz, the increased
incidence of severe malaria that was observed in chronic HBV
carriers was explained by reduced expression of HLA class I
molecules by hepatocytes during chronic HBV infection [3]. HLA
class I molecules are important in the recognition and subsequent
lysis of P. falciparum infected hepatocytes by cytotoxic T lymphocytes
(CTLs). Thus, the lysing of parasite-infected hepatocytes by
cytotoxic T lymphocytes (CTLs) may have been impaired in
HBV carriers leading to an increased susceptibility to severe
malaria. Whether similar mechanisms play a role in the association
of acute HAV and falciparum malaria remains unclear.
In conclusion, we provide tentative evidence for a temporal
association between P. falciparum and HAV infections in children living
in an area of high P. falciparum and HAV transmission. Unfortunately,
there is very limited information available about baseline HAV rates
in Kenya, which is needed to draw stronger conclusions. We did not
measure this; nevertheless we observed a temporal association
between falciparum malaria and HAV. Prospective and larger studies
are required to further elucidate the epidemiological interaction
between these two important human pathogens. Our data also
highlight the need for more comprehensive analyses of the complex
interactions of prevalent infectious diseases in endemic countries that
contribute to an unacceptably high disease burden.
Materials and Methods
Study site
The study was conducted at the Pingilikani study site of the
Kenya Medical Research Institute/Centre for Geographic
Medicine Research-Coast (CGMR-C). The Pingilikani study site
is located 20 km south of Kilifi town in Kilifi district along the
Kenyan coast [18]. P. falciparum transmission rates have been
estimated to range between 22 and 53 infective bites per person
per year [19]. Currently there is no data on the incidence of
HAV or any other hepatitis viruses in this age group in Kilifi
District.
Study design and patients
This study was nested in an ongoing clinical trial to assess the
efficacy and safety of dihydroartemisinin-piperaquine in compar-
ison with artemether-lumefantrine in children with uncomplicated
P. falciparum malaria [20] and Borrmann et al (unpublished data).
Ethical approval for this study was granted by the Kenya National
Ethics Review Committee, the Oxford Tropical Research Ethics
Committee and the Ethics Committee of the Heidelberg
University School of Medicine. Children aged 6–59 months
presenting to the Pingilikani Health Centre with symptoms
suggestive of uncomplicated malaria and a documented P.
falciparum infection with an asexual parasite density of 2,000–
200,000 parasites/mL, were recruited. Written informed consent
was obtained from the parents. Patients were monitored daily until
parasite and fever clearance was achieved. Active follow-up was on
days 3 and 7, then weekly on days 14, 21, 28, 35, 42, 56, and 63
and 84. All subjects were seen on any day between day 0 and 84
upon request. ALT was measured routinely at baseline and at day
3, 7, 28, 42, 84, and at asexual parasite recurrence. Although ALT
levels in patients with active HAV infection are typically 4–100
times elevated [21], we determined acute HAV infection status in
all available samples with ALT levels of .36 U/L which is the
upper limit of normal in children. In order to identify whether false
positive tests were occurring at high parasite density, acute HAV
infection status was also determined in children who had a
baseline parasitemia of .150,000/mL. We used samples from
baseline to measure anti-HAV IgM titers in any sample with
elevated ALT from baseline up to day 7 as we assumed that the
anti-HAV IgM levels would not significantly change during this
period. For the other time-points (day 28, 42, and 84) we used
blood samples from the respective study days.
Laboratory procedures
Malaria infection was confirmed by Giemsa-stained thick smear
[22]. We used a commercial ELISA kit to detect IgM antibodies to
HAV (ELISA Kit for IgM Antibody to Hepatitis A Virus,
BioChain, USA). The assay was performed according to the
manufacturer’s instructions.
Statistical analysis
Analysis was carried out using Stata version 9.2 (Statacorp,
Texas, USA). Data were entered and checked for inconsistencies
by two different persons to reduce faulty entries. The Kolmo-
gorov-Smirnov test was used to verify the normality of distribution
of continuous variables. Comparisons between groups were
performed using the t-test or two-tailed unpaired Mann-Whitney
test for continuous variables evaluated as normally distributed and
not-normally distributed, respectively. The chi-square test was
used for comparisons between categorical variables. Parasitemia
results were summarized using geometrical means and 95%
confidence intervals. All the remaining continuous variables were
reported with arithmetic means and standard deviation, or by the
median and IQR. P,0.05 was considered statistically significant.
Exact binomial confidence intervals were calculated to compare
incidence rates.
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